INS and type 2 diabetes mellitus: Supporting this observation, individuals with specific genetic variations in genes targeted by LDL-C-lowering therapies (e.g. HMGCR, NPC1L1, PCSK9) exhibit impaired insulin sensitivity and a greater propensity to develop type 2 diabetes, particularly those with impaired glucose tolerance [58].